BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Novozymes Biopharma's rAlbumin Approved in Japan as MAQUET Expands Into New Market


2/28/2013 11:36:18 AM

NOTTINGHAM, UK – February 27, 2013 – Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, has announced that one of its leading customers has achieved approval of a medical device in Japan using Recombumin® Alpha - formerly Albucult®, a recombinant human albumin (rAlbumin) product. Recombumin Alpha is used by MAQUET in a version of the company’s proprietary BIOLINE Coating, which has already received regulatory approval and is being used successfully in many countries around the world. This approval represents yet another landmark registration for Novozymes Biopharma’s Recombumin portfolio and the first for a medical device product in Japan. The use of Recombumin Alpha in MAQUET’s BIOLINE Coating confers a range of unique advantages due to its stable, pure and safe composition, meaning that it can enable manufacturers to streamline their regulatory approval processes and accelerate a product’s time-to-market.

Novozymes’ rAlbumins have been assisting MAQUET in developing safe, regulatory compliant products for over 10 years as part of an ongoing strategic partnership between the two companies. The BIOLINE Coating has been developed by MAQUET to improve the biocompatibility of extracorporeal circulation system devices, such as oxygenators, which come into contact with blood during heart surgery. Whether for oxygenators, centrifugal pumps, filters, reservoirs, venous bubble traps, catheters and cannulae, tubes or tubing set accessories, a consistent quality of BIOLINE Coating is supplied for all applications. The use of Recombumin Alpha contained in the version of BIOLINE Coating approved for the Japanese market helps to improve the biocompatibility of these devices, while its unmatched safety and purity profile minimizes the risk of contamination and impurities.

Dr. Wolgang Rencken, President and CEO at MAQUET Cardiopulmonary AG comments: “With Novozymes’ rAlbumin, MAQUET is now able to offer our highly biocompatible BIOLINE Coating in Japan. Reducing negative side effects on blood when it comes into contact with foreign surfaces, such as polycarbonates or tubings, has always been one of MAQUET’s focus areas in extracorporeal circulation. We are very happy to offer this advantage to our customers and especially their patients in Japan. ”

Dermot Pearson, Marketing Director at Novozymes Biopharma comments, “We are delighted that Recombumin Alpha is a component of a medical device product now approved for the Japanese market. As a business, Novozymes is conscious of the rapidly changing regulatory landscape with regulations becoming increasingly tighter. As a result, we are committed to assisting our partners in developing safe, stable and highly pure products using ingredients which are Q7 compliant.” Dermot continues, “Our long-term relationship as a strategic partner to MAQUET has worked through mutual understanding of the company’s goals and Novozymes’ deep knowledge of the regulatory processes involved in taking product to market.”

Novozymes’ rAlbumins are compliant with the National Formulary (NF) rAlbumin human monograph published by the United States Pharmacopeia (USP). The use of Recombumin Alpha offers a range of performance and quality benefits for these applications, including sustainability of supply, improved biocompatibility and GMP compliance. Novozymes’ also ensures batch-to-batch consistency to reduce processing and testing times to drive product efficiency for customers looking for a compliant albumin alternative.

For further information on Novozymes Biopharma’s Recombumin portfolio please visit www.biopharma.novozymes.com

About Novozymes

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries, we create tomorrow’s industrial biosolutions, improving our customers' business and the use of our planet's resources.

With over 700 products used in 130 countries, Novozymes’ bioinnovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever-changing marketplace. Read more at www.novozymes.com.

Contact:

Novozymes Biopharma:

Sally Vernon, Customer Communications Manager

SYKE@novozymes.com

Tel. +44 1159551209

MEDIA CONTACTS

Europe

René Tronborg

Office: +45 4446 2274

Mobile: +45 3077 2274

retr@novozymes.com

China

Zhu Xiaoqing

Office: +86 106 298 7888+362

Mobile: +86 138 012 40590

xqzh@novozymes.com

US

Paige Donnelly

Office: +1 919 494 3209

Mobile: +1 919 218 4501

pagd@novozymes.com

Brazil

Ana Cecilia Amarante de Oliveira

Office: +55 41 3641 1096

Mobile: +55 41 9619 7594

aaov@novozymes.com

INVESTOR CONTACTS

US

Thomas Steenbech Bomhoff

Mobile: +1 919 649 2565

tsbm@novozymes.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES